Statins for multiple sclerosis [2] (multiple letters)

Lancet

Volumn 364, Issue 9432, 2004, Pages 412-413

  Sena, Armando ^a,b   Pedrosa, Rui ^a   Graca Morais M ^a,b   Laroche, Marie Laure ^c   Merle, Louis ^c   Vollmer, Timothy ^d   Singh, Inderjit ^d  

^a HOSPITAL DOS CAPUCHOS   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; CREATINE KINASE;

BLOOD BRAIN BARRIER; DISEASE COURSE; DOSE RESPONSE; DRUG INHIBITION; FOLLOW UP; HUMAN; LETTER; MONOTHERAPY; MULTIPLE SCLEROSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZATION; REDUCTION; RELAPSE; BRAIN; NOTE; PATHOLOGY; RECURRENT DISEASE; CHEMICALLY INDUCED DISORDER; METABOLISM; RHABDOMYOLYSIS;

BRAIN; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; RHABDOMYOLYSIS;

EID: 3843080961     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16752-4     Document Type: Letter

References (4)

1. T Vollmer L Key V Durkalski Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607 1608
2. CH Polman J Killestein Statins for the treatment of multiple sclerosis: cautious hope Lancet 363 2004 1570
3. A Sena R Pedrosa MG Morais Therapeutic potential of lovastatin in multiple sclerosis J Neurol 250 2003 754 755
4. JG Schulz J Bösel M Stoeckel D Megow U Dirnagl M Endres HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranyl pyrophosphate synthesis J Neurochem 89 2004 24 32